Modern capacities of the control of early carbohydrate metabolism disorders


DOI: https://dx.doi.org/10.18565/therapy.2018.5.33-39

T.Ju. Demidova, F.O. Ushanova

The Department of endocrinology of Federal State Budgetary Educational Institution of Higher Professional Education «N.I. Pirogov RNRMU», Moscow, Russia
The prevalence of type 2 diabetes mellitus (DM2) and prediabetes in recent years has been steadily increasing. The increase in the number of patients with diabetes is a serious threat to the entire population and could be considered to be the one of the main medical and social problems of public health. Effective measures of primary prevention of diabetes is the most rational way to increase the life expectancy of patients and improve their quality of life. In recent years throughout the world have been taken measur to identify opportunities for preventing development and delaying the clinical manifestation of diabetes melitus2. Non-pharmacological and medication interventions used at the «pre-diabetes» stages, the most effective of which are 5-10% body weight reduction by correcting the diet, increasing physical activity and taking metformin,  can significantly reduce the risk of the disease.
Keywords: type 2 diabetes melitus, pre-diabetes, impaired glucose tolerance, hyperglycemia on an empty stomach, metformin
Read entire article

Literature

  • Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999; 354: 617–21.
  • Anselmino M., O¨ hrvik J., Malmberg K., Standl E., Ryden L. Euro Heart Survey Diabetes and the Heart Newly detected diabetes: Combined cardiovascular events with or without prescribed pharmacological glucose-lowering treatment. Euro. Heart J. 2008; 29: 177–84.
  • IDF, Диабетический атлас, 8 издание. 2017.
  • Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19(2): 104–12.
  • Аметов А.С. и др. Проект клинических рекомендаций Профилактика развития сахарного диабета 2 типа: роль и место метформина. Эндокринология. 2017; 1: 1–6.
  • Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2017; 1(11): 94–5.
  • Чазова И.Е., Недогода С.В., Жернакова Ю.В. и др. Рекомендации по ведению больных с метаболическим синдромом. Клинические рекомендации. М., 2013. С. 26–8.
  • Garber A.J. et al. AACE/ACE Comrehensive type 2 diabetes management algorithm 2017. Endocr. Pract. 2017;23(2):207–27.
  • Diabetes Prevention Program Research Group. N. Engl. J. Med. 2002;346:393–403.
  • DPPOS. Lancet Diabetes Endocrinol. Published online September 14. 2015. http: //dx.doi.org./10.1016/S2213-8587(15)00291-0.
  • Chiasson J.L., Josse R.G., Gomis R. et al. Acarbose for prevention of type 2 diabetes mellitus: The Stop-NIDDM trial. Lancet. 2002;359:2072–7.
  • Мычка В.Б., Чазова И.Е., Беленков Ю.Н. Первые результаты российской программы по изучению эффективности применения акарбозы у пациентов с нарушенной толерантностью к глюкозе и артериальной гипертонией (АПРЕЛЬ). Кардиоваскулярная терапия и профилактика. 2004;3(6):66–73.
  • Zinman B., Harris S.B., Neuman J. at al. Low-dose combination therapy with rosiglitazone and metformine to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomized controlled study. Lancet. 2010;376:103–11.
  • The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006;355(15):1551–62.
  • Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.
  • Pi-Sunyer X., Astrup A., Fujioka K. et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015;373:11–22.


    • About the Autors

    Tatjana Ju. Demidova, MD, professor, head of the Department of endocrinology of the general medicine faculty of Federal State Budgetary Educational Institution of Higher Professional Education «N.I. Pirogov RNRMU». Tel.: +74991798506; e-mail: t.y.demidova@gmail.com.
    Fatima O. Ushanova, assistant professor of the Department of endocrinology of the general medicine faculty of Federal State Budgetary Educational Institution of Higher Professional Education «N.I. Pirogov RNRMU».
    Tel.: +79250111010. E-mail: fati_2526@mail.ru.

    Back to Content

    Бионика Медиа